Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV000184034 | SCV003824821 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2022-12-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000184034 | SCV004299490 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2022-11-23 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PDHA1 protein function. ClinVar contains an entry for this variant (Variation ID: 202188). This missense change has been observed in individual(s) with pyruvate dehydrogenase lipoic acid synthetase deficiency (PMID: 10679936). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 141 of the PDHA1 protein (p.Arg141Gln). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg141 amino acid residue in PDHA1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11757583). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. |
Mendelics | RCV000184034 | SCV000236565 | pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2013-09-23 | no assertion criteria provided | clinical testing |